Ber-EP4

Ber-EP4 is an antibody used in pathology to detect a protein (EpCAM) found on the surface of most adenocarcinoma cells but generally absent from mesothelioma cells. Pathologists apply it to biopsy tissue as part of an immunohistochemistry panel to help tell mesothelioma apart from lung or other adenocarcinomas that have spread to the pleura. A positive Ber-EP4 stain points away from mesothelioma; a negative stain is consistent with (but does not by itself prove) mesothelioma.

Origin

The Ber-EP4 monoclonal antibody was developed by Latza and colleagues in Berlin, Germany in 1990. The "Ber" refers to Berlin, and "EP" stands for epithelial. It quickly became one of the standard "carcinoma markers" used in pleural and peritoneal pathology.

Significance in Asbestos Context

For a patient with suspected mesothelioma, the diagnosis almost always rests on a biopsy interpreted with an immunohistochemistry panel, and Ber-EP4 is one of the markers most commonly used to rule out metastatic adenocarcinoma (especially from the lung) mimicking mesothelioma. Getting this distinction right matters enormously: mesothelioma carries a strong presumption of asbestos causation and qualifies patients for trust-fund claims and lawsuits, while a lung adenocarcinoma diagnosis follows a different treatment path and a different legal analysis. If your pathology report mentions Ber-EP4, look at whether it was positive or negative and how it fit with other markers (calretinin, WT-1, D2-40, CK5/6, claudin-4, MOC-31, TTF-1); a single marker is never decisive, and ambiguous cases often benefit from expert mesothelioma pathology review.

Example Sentence

The pathologist reported that the tumor cells were negative for Ber-EP4 and positive for calretinin and WT-1, supporting a diagnosis of epithelioid mesothelioma rather than metastatic lung adenocarcinoma.

Related Terms

Immunohistochemistry, Epithelioid Mesothelioma, Adenocarcinoma, Calretinin, WT-1, MOC-31

Notes

• Request a copy of your full pathology report (not just the summary) so you can see which immunohistochemical markers were tested and the result of each, including Ber-EP4.
• If your diagnosis is uncertain or based on a small biopsy, ask your oncologist about a second pathology opinion at a mesothelioma specialty center (such as an NCI-designated cancer center or the US/International Mesothelioma Panel). Misclassification between mesothelioma and adenocarcinoma directly affects both treatment and legal claims.
• Preserve the original biopsy slides and paraffin blocks; your legal team or a reviewing expert may need them re-stained, and hospitals can discard tissue after a set retention period.
• Ber-EP4 can occasionally be weakly positive in mesothelioma and negative in some adenocarcinomas, which is why current guidelines recommend at least two mesothelial and two carcinoma markers before making a final diagnosis.